7 completed, 3 recruiting, 3 unknown, 2 enrolling by invitation. 4 Not applicable, 4 Phase 2, 4 Phase 3, 3 Phase 1, 1 Phase 4.
Follow Chemotherapy-Induced Nausea and Vomiting (CINV): new trials by email Literature Review of Chemotherapy-Induced Nausea and Vomiting (CINV) trials Research Report on Chemotherapy-Induced Nausea and Vomiting (CINV)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare the Bioavailability of Ondansetron Following Nasal (NS003) and IV Administration in Healthy Adults NS003 Ondansetron HCl microspheres powder for nasal application, Ondansetron Solution for IV infusion 8mg - Chemotherapy-Induced Nausea and Vomiting (CINV), Radiotherapy-induced Nausea and Vomiting (RINV) | Phase 1 | Recruiting | Nasus Pharma | 12 | 2026-09-15 | 2026-10-09 |
| QLM2010 Comparative Pharmacokinetic Study With 2-Minute Intravenous Administration apripitant and palonosetron injectable emulsion, palonosetron hydrochloride injection, apripitant injection (CINVANTI) - Chemotherapy-Induced Nausea and Vomiting (CINV) | Phase 1 | Not yet recruiting | Qilu Pharmaceutical (Hainan) Co., Ltd. | 42 | 2026-09-01 | 2026-09-14 |
| HR20013 for the Prevention of Nausea and Vomiting in Patients With Cancer: A Real-World Study Chemotherapy-Induced Nausea and Vomiting (CINV), Nausea | Recruiting | Sun Yat-sen University | 3000 | 2026-07-15 | 2026-10-14 | |
| Acupuncture to Prevent Nausea and Vomiting After Stem Cell Transplant Acupuncture, Conventional care - Chemotherapy-Induced Nausea and Vomiting (CINV), Hematopoietic Stem Cell Transplantation (HSCT) | Not applicable | Enrolling by invitation | Xiao Wang | 80 | 2026-07-01 | 2026-08-05 |
| Fosrolapitant Combined With Palonosetron to Prevent Trastuzumab Rezetecan Related CINV Fosrolapitant and Palonosetron Hydrochloride for Injection - Chemotherapy-Induced Nausea and Vomiting (CINV) | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 56 | 2026-06-15 | 2026-07-24 |
| Nano-crystalline Megestrol Acetate for Chemotherapy-induced Nausea and Vomiting nanocrystalline megestrol acetate combined with ondansetron, dexamethasone combined with ondansetron - Chemotherapy-Induced Nausea and Vomiting (CINV) | Phase 2 | Not yet recruiting | AIPING ZHOU | 127 | 2025-12-01 | 2025-11-24 |
| Effect of Mandala Coloring on Nausea, Fatigue, and Well-Being in Chemotherapy Patients Mandala Coloring Intervention - Chemotherapy-Induced Nausea and Vomiting (CINV) | Not applicable | Completed | University of Gaziantep | 85 | 2025-12-01 | 2026-10-08 |
| Evaluating the Feasibility and Acceptability of Inhalation Aromatherapy for Patients Undergoing Autologous Haematopoietic Stem Cell Transplant (HSCT) Aromatherapy inhaler, Aromatherapy inhaler (placebo) - Chemotherapy-Induced Nausea and Vomiting (CINV) | Not applicable | Enrolling by invitation | Singapore General Hospital | 30 | 2025-05-15 | 2025-12-22 |
| Geranium Inhalation Aromatherapy for Reducing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy Geranium Inhalation Aromatherapy - Chemotherapy-Induced Nausea and Vomiting (CINV), Cancer | Not applicable | Completed | Universitas Muhammadiyah Surakarta | 90 | 2024-01-01 | 2025-12-18 |
| Safety Study of Repeat Doses of SUSTOL in Adults SUSTOL - Chemotherapy-Induced Nausea and Vomiting (CINV) | Phase 4 | Unknown | Heron Therapeutics | 300 | 2022-07-06 | 2023-07-28 |
| Granisetron Transdermal Patch for Prophylaxis of Delayed CINV Granisetron transdermal patch, Palonosetron, Aprepitant - Chemotherapy-induced Nausea and Vomiting (CINV) | Phase 3 | Unknown | Fudan University | 140 | 2021-06-10 | 2021-06-03 |
| Granisetron Transdermal Patch for Prophylaxis of Nausea and Vomiting in Patients Receiving Oral Anticancer Agents Granisetron Transdermal Delivery System - Chemotherapy-induced Nausea and Vomiting (CINV) | Phase 2 | Unknown | Fudan University | 60 | 2020-07-18 | 2022-04-20 |
| PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting Netupitant, Palonosetron - Chemotherapy-induced Nausea and Vomiting (CINV) | Phase 2 | Completed | Helsinn Healthcare SA | 67 | 2017-08-31 | 2024-06-25 |
| Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031) Fosaprepitant dimeglumine, Fosaprepitant Placebo, Dexamethasone - Chemotherapy-Induced Nausea and Vomiting (CINV) | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1015 | 2012-09-24 | 2018-09-04 |
| Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183) Fosaprepitant 150 mg, Aprepitant 165 mg, Aprepitant 250 mg - Chemotherapy-Induced Nausea and Vomiting (CINV) | Phase 1 | Completed | Merck Sharp & Dohme LLC | 16 | 2010-04-01 | 2015-02-25 |
| Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED) aprepitant, Comparator: Placebo to aprepitant, dexamethasone - Chemotherapy-induced Nausea and Vomiting (CINV) | Phase 3 | Completed | Merck Sharp & Dohme LLC | 421 | 2009-08-25 | 2017-06-02 |
| Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017) Comparator: fosaprepitant dimeglumine, Comparator: Aprepitant, Dexamethasone - Chemotherapy-Induced Nausea and Vomiting (CINV) | Phase 3 | Completed | Merck Sharp & Dohme LLC | 2322 | 2008-02-01 | 2017-03-21 |
Vomiting (17) · Nausea (3) · Neoplasms (2) · Fatigue (1) · Postoperative Nausea and Vomiting (1) · Psychological Well-Being (1)
Pathological Conditions, Signs and Symptoms (17) · Signs and Symptoms (17) · Signs and Symptoms, Digestive (17) · Behavior (1) · Nausea (1) · Pathologic Processes (1) · Personal Satisfaction (1) · Postoperative Complications (1)
Aprepitant (5) · Dexamethasone (5) · Granisetron (4) · Ondansetron (4) · Palonosetron (4) · fosaprepitant (3) · Acupuncture Therapy (1) · Aromatherapy (1) · Calcium Dobesilate (1) · Infusions, Intravenous (1) · Injections (1) · Injections, Subcutaneous (1) · netupitant (1)
Merck Sharp & Dohme LLC (4) · Fudan University (2) · AIPING ZHOU (1) · Helsinn Healthcare SA (1) · Heron Therapeutics (1) · Nasus Pharma (1) · Qilu Pharmaceutical (Hainan) Co., Ltd. (1) · Singapore General Hospital (1) · Sun Yat-sen University (1) · Tianjin Medical University Cancer Institute and Hospital (1) · Universitas Muhammadiyah Surakarta (1) · University of Gaziantep (1) · Xiao Wang (1)
China (4) · United States (2) · Indonesia (1) · Israel (1) · Russia (1) · Serbia (1) · Singapore (1) · Turkey (Türkiye) (1) · Ukraine (1)
Cheryl Tay, Bachelor of Nursing (1) · Xichun Hu, Prof. (1)
PMID 21383291, PMID 22739139, PMID 24276953, PMID 26449391, PMID 29808377, PMID 32988373, PMID 41520166, PMID 42776270